Skip to content
thispeptide

One80Rx

One80Rx offers compounded GLP-1 care alongside a large peptide catalog, with check-ins and direct messaging described. The assigned practice, pharmacy and evidence for each additional therapy need closer attention.

Review by Leah Garner, clinical-evidence editor · Updated October 2026

The short version

Evaluate the actual prescription rather than treating the whole menu as one proven program. The care contact is a useful feature to confirm, but the catalog includes compounds with substantial evidence and safety limitations.

Disclosure: This Peptide is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.

One80Rx LLC operates a telehealth platform for compounded semaglutide, tirzepatide and additional clinician-reviewed therapies. The GLP-1 catalog identifies injectable options alongside an unspecified oral GLP-1 program. Other listed treatments include sermorelin, NAD+ and PT-141. NAD+ is a coenzyme, not a peptide. The presence of a treatment page does not establish that it is clinically suitable, available in every state or supported for every advertised goal. The exact compound and preparation should be confirmed before an eligibility result becomes a treatment decision.

What One80Rx prescribes, by goal

Weight

  • SemaglutideFDA-approved

    Listed by the seller; no price we hold.

    • TirzepatideFDA-approved

      Listed by the seller; no price we hold.

      The semaglutide program describes a weekly injection and clinician-directed adjustment. Its timeline associates a substantial average reduction with six months, while the referenced branded trial has a different follow-up duration. That figure is not a demonstrated result for an One80Rx compounded preparation.

      Sexual health

      PT-141 is presented as an as-needed subcutaneous injection and promoted for women and men. That broad marketing audience should not be confused with the specific indication of an approved branded bremelanotide product. Confirm the formulation, proposed use and relevant evidence.

      Longevity

      • NAD+Compounding conditions apply

        Listed by the seller; no price we hold.

        Recovery

        • SermorelinCompounding conditions apply

          Listed by the seller; no price we hold.

          Sleep

          • SermorelinCompounding conditions apply

            Listed by the seller; no price we hold.

            DSIP is marketed in the cognitive and neurological catalog. A research rationale or a catalog listing is not evidence of a reliable sleep treatment. FDA identifies important safety and human-data limitations for certain compounded ingredients, including DSIP.

            Who prescribes

            A licensed clinician

            The website describes a licensed clinician network but does not name the assigned practitioner, treating medical group or dispensing pharmacy. The platform disclaimer separates those clinical and pharmacy roles from One80Rx itself. Ask who takes responsibility for assessment, prescribing, monitoring and an urgent medication concern. US pharmacy sourcing without a facility name is not enough to verify the actual dispenser. State-specific availability also needs confirmation rather than relying on the general nationwide headline.

            The program describes a consultation before any prescription. A clinician reviews the health assessment and decides whether a treatment is appropriate. Structured check-ins and direct secure messaging are advertised for GLP-1 care. The homepage also describes follow-ups arranged as needed, so a fixed recurring clinical appointment interval is not established. Clarify who answers messages, when a dose change is reviewed and how care continues if treatment is paused. The additional peptide pathway should have its own assessment rather than automatically inheriting every GLP-1 service promise.

            Are labs required?

            Not mentioned

            Laboratory review is mentioned as something a plan may respond to, but a universal testing requirement or included panel is not established. Ask which measurements support the selected therapy and who evaluates them over time. That matters especially for growth-hormone-oriented treatments with a different monitoring question from GLP-1 care. No complete laboratory price is published in the cited program.

            Ready to start with One80Rx?

            Prices and plans are set on the seller's own site.

            What it claims, and what it cites

            The catalog includes BPC-157, CJC-1295, ipamorelin, MOTS-c and other experimental ingredients. FDA identifies significant safety concerns or insufficient human information for a number of these substances. A mechanistic explanation does not establish a clinical recovery, longevity or neurological benefit. The supplier’s own disclaimer also acknowledges that compounded products are not FDA-approved. Branded-drug trial results cannot prove that a separate compounded product produces the same outcome or timeline.

            Other products and treatment claims

            BPC-157, DSIP, MOTS-c and other experimental catalog therapies
            A current listing is not an endorsement; FDA safety concerns and limited clinical evidence require substance-specific evaluation.
            Unspecified oral GLP-1 preparation
            The catalog does not establish the exact active ingredient and form for a drug-specific comparison row.

            How it bills

            The catalog uses starting figures while the GLP-1 detail pages reserve a plan quote for consultation. Flat-rate and no-dose-surcharge claims do not themselves identify the complete offered supply. The semaglutide FAQ asks for thirty days of cancellation notice, whereas the legal agreement gives a forty-eight-hour portal cutoff. Resolve that conflict in writing before agreeing to recurring care. Confirm any laboratory and pharmacy charges alongside the actual prescription.

            For and against

            • For: Clinical review required
            • For: Secure messaging described
            • For: GLP-1 check-ins advertised
            • For: Compounding disclaimer present
            • Against: Treating practice and pharmacy unnamed
            • Against: Experimental menu carries evidence limits
            • Against: Trial timelines need careful context
            • Against: Cancellation instructions conflict

            The evidence behind what it sells

            Right for

            Someone prepared to assess a specific proposed preparation and verify the assigned medical team and continuing review.

            Look elsewhere if

            Someone treating all listed peptides as established therapies or expecting a catalog timeline to predict individual results.

            Other sellers for weight

            One80Rx

            Frequently asked questions

            Does the catalog establish that every peptide is proven?
            No. FDA identifies safety concerns and limited human data for several listed compounding ingredients. Each proposed treatment needs its own evidence assessment.
            Is NAD+ a peptide?
            No. The product page identifies NAD+ as a coenzyme. Its listing does not establish a longevity benefit.
            Is there one clear cancellation deadline?
            No. The program FAQ describes thirty days of notice, while the legal subscription section gives a forty-eight-hour cutoff. Confirm the applicable agreement before payment.

            Sources

            See what One80Rx prescribes today

            One80Rx sets its own prices, plans and the states it serves. Check them before you start.

            Written by Leah Garner from One80Rx’s own public pages, against the published methodology. No outcome is claimed first-hand and no score is given. A partnership never changes what this page says; see how the site is paid.